| Literature DB >> 28695135 |
N S Zakharchenko1, A S Belous2,3, Y K Biryukova4,5, O A Medvedeva2, A V Belyakova5, G A Masgutova6, E V Trubnikova2,3, Y I Buryanov1, A A Lebedeva1.
Abstract
Previously transgenic Kalanchoe pinnata plants producing an antimicrobial peptide cecropin P1 (CecP1) have been reported. Now we report biological testing K. pinnata extracts containing CecP1 as a candidate drug for treatment of wounds infected with Candida albicans. The drug constitutes the whole juice from K. pinnata leaves (not ethanol extract) sterilized with nanofiltration. A microbicide activity of CecP1 against an animal fungal pathogen in vivo was demonstrated for the first time. However, a favorable therapeutic effect of the transgenic K. pinnata extract was attributed to a synergism between the fungicide activity of CecP1 and wound healing (antiscar), revascularizing, and immunomodulating effect of natural biologically active components of K. pinnata. A commercial fungicide preparation clotrimazole eliminated C. albicans cells within infected wounds in rats with efficiency comparable to CecP1-enriched K. pinnata extract. But in contrast to K. pinnata extract, clotrimazole did not exhibit neither wound healing activity nor remodeling of the scar matrix. Taken together, our results allow assumption that CecP1-enriched K. pinnata extracts should be considered as a candidate drug for treatment of dermatomycoses, wounds infected with fungi, and bedsores.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28695135 PMCID: PMC5485323 DOI: 10.1155/2017/3940743
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Figure 1Planimetry examination of healing of the wounds in rats infected with C. albicans. Wound recovery percentage at 10th and 14th days after beginning of curing is shown (M ± Std. Dev.).
Figure 2Duration of the wound recovery phases in rats (infected with C. albicans) after beginning of curing (M ± Std. Dev.).
Figure 3Histological analysis of derma in the wound bed, day 3 after beginning of curing (magnif. ×280). (a) Positive control (clotrimazole); (b) negative control (mock); (c) reference group (wild-type K. pinnata); (d) experimental group (CecP1). Selected area: circle/oval—edema in derma, arrow—leucocyte infiltration in the derma.
Figure 4Histological analysis of derma within the wound bed, day 10 after the beginning of curing (magnif. ×70). (a) Positive control (clotrimazole); (b) negative control (no specific treatment); (c) reference group (wild-type K. pinnata extract); (d) experimental group (CecP1). Selected area: arrow—new-formed thin epithelium, square—area of melting of the necrotic tissue.
Figure 5Histological analysis of derma in the wound bed, day 14 after the beginning of curing (magnif. ×280). (a) Positive control (clotrimazole); (b) negative control (no specific treatment); (c) reference group (wild-type K. pinnata extract); (d) experimental group (CecP1). Selected area: arrow—fibroblasts, circle—collagen fibers, and double arrow—thickened epidermis.
Figure 6Dynamics of the wound bed contamination with C. albicans.